Clinical Trial Update: A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and activity of Sparsentan in incident patients with immunoglobulin A nephropathy; the trial is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Sparsentan (sparsentan)

Snippet

Sponsor: University of Leicester | Conditions: Immunoglobulin A Nephropathy, Kidney Diseases | Phase 2 | Status: ACTIVE_NOT_RECRUITING